# Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

> **NCT07067450** · NA · NOT_YET_RECRUITING · sponsor: **Sichuan University** · enrollment: 98 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab)
- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT07067450
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07067450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07067450, "Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07067450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*